Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?

Hindryckx P, Vande Casteele N, Novak G, Khanna R, D'Haens G, Sandborn WJ, Danese S, Jairath V, Feagan BG.

J Crohns Colitis. 2018 Jan 5;12(1):105-119. doi: 10.1093/ecco-jcc/jjx117. Review.

PMID:
28961959
2.

New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease.

Bravatà I, Fiorino G, Allocca M, Repici A, Danese S.

Scand J Gastroenterol. 2015 Jan;50(1):113-20. doi: 10.3109/00365521.2014.993700. Review.

PMID:
25523561
3.

The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews.

Khanna R, Chande N, Vermeire S, Sandborn WJ, Parker CE, Feagan BG.

Inflamm Bowel Dis. 2016 Jul;22(7):1737-43. doi: 10.1097/MIB.0000000000000808. Review.

PMID:
27306074
4.

Novel targets for inflammatory bowel disease therapeutics.

Löwenberg M, D'Haens G.

Curr Gastroenterol Rep. 2013 Feb;15(2):311. doi: 10.1007/s11894-012-0311-3. Review.

PMID:
23314806
5.

Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.

McLean LP, Cross RK.

Expert Opin Drug Metab Toxicol. 2016 Jul;12(7):833-42. doi: 10.1080/17425255.2016.1181171. Epub 2016 May 12. Review. Erratum in: Expert Opin Drug Metab Toxicol. 2016 Jul;12 (7):v.

6.

Vedolizumab for the treatment of moderately to severely active ulcerative colitis.

Dulai PS, Mosli M, Khanna R, Levesque BG, Sandborn WJ, Feagan BG.

Pharmacotherapy. 2015 Apr;35(4):412-23. doi: 10.1002/phar.1561. Review. Erratum in: Pharmacotherapy. 2015 Oct;35(10):979.

PMID:
25884529
7.

Efficacy and safety of vedolizumab in the treatment of ulcerative colitis.

Domènech E, Gisbert JP.

Gastroenterol Hepatol. 2016 Dec;39(10):677-686. doi: 10.1016/j.gastrohep.2015.11.010. Epub 2016 Mar 2. Review. English, Spanish.

PMID:
26948838
8.

Therapy of inflammatory bowel disease: what to expect in the next decade.

Leiman DA, Lichtenstein GR.

Curr Opin Gastroenterol. 2014 Jul;30(4):385-90. doi: 10.1097/MOG.0000000000000077. Review.

PMID:
24902037
9.

Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.

Lam MC, Bressler B.

Immunotherapy. 2014;6(9):963-71. doi: 10.2217/imt.14.66.

PMID:
25341118
10.

Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.

Molander P, Sipponen T, Kemppainen H, Jussila A, Blomster T, Koskela R, Nissinen M, Rautiainen H, Kuisma J, Kolho KL, Färkkilä M.

J Crohns Colitis. 2013 Oct;7(9):730-5. doi: 10.1016/j.crohns.2012.10.018. Epub 2012 Nov 21.

PMID:
23182163
11.

The role of integrin antagonists in the treatment of inflammatory bowel disease.

Beniwal-Patel P, Saha S.

Expert Opin Biol Ther. 2014 Dec;14(12):1815-23. doi: 10.1517/14712598.2014.967209. Epub 2014 Oct 7. Review.

PMID:
25288228
12.

Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.

Hagan M, Cross RK.

Expert Opin Drug Saf. 2015;14(9):1473-9. doi: 10.1517/14740338.2015.1063612. Epub 2015 Jul 9. Review.

PMID:
26138111
13.

Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases.

Saruta M, Papadakis KA.

Gastroenterol Clin North Am. 2014 Sep;43(3):581-601. doi: 10.1016/j.gtc.2014.05.012. Epub 2014 Jun 25. Review.

PMID:
25110260
14.

Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment.

Vuitton L, Koch S, Peyrin-Biroulet L.

Curr Drug Targets. 2013 Nov;14(12):1385-91. Review.

PMID:
23627915
15.

Ustekinumab: moving the target from psoriasis to Crohn's disease.

Settesoldi A, Coppola M, Rogai F, Annese V.

Expert Rev Gastroenterol Hepatol. 2014 Jan;8(1):5-13. doi: 10.1586/17474124.2014.850414. Epub 2013 Nov 25. Review.

PMID:
24410468
16.

Vedolizumab for the treatment of ulcerative colitis and Crohn's disease.

McLean LP, Shea-Donohue T, Cross RK.

Immunotherapy. 2012 Sep;4(9):883-98. doi: 10.2217/imt.12.85. Review.

17.

[Vedolizumab in the treatment of Crohn's disease].

Gisbert JP, Domènech E.

Gastroenterol Hepatol. 2015 May;38(5):338-48. doi: 10.1016/j.gastrohep.2014.12.003. Epub 2015 Jan 23. Review. Spanish.

PMID:
25619903
18.

Update on ustekinumab for the treatment of Crohn's disease.

Leung Y, Panaccione R.

Gastroenterol Clin North Am. 2014 Sep;43(3):619-30. doi: 10.1016/j.gtc.2014.05.013. Review.

PMID:
25110262
19.

Drug therapy of inflammatory bowel disease.

Sack DM, Peppercorn MA.

Pharmacotherapy. 1983 May-Jun;3(3):158-76. Review.

PMID:
6136027
20.

Vedolizumab for the treatment of ulcerative colitis.

Shahidi N, Bressler B, Panaccione R.

Expert Opin Biol Ther. 2016;16(1):129-35. doi: 10.1517/14712598.2016.1121231. Epub 2015 Dec 9. Review.

PMID:
26567768

Supplemental Content

Support Center